Skip to main content
Premium Trial:

Request an Annual Quote

Nirmidas Closes $2M Funding Round

Premium

NEW YORK (GenomeWeb) – Stanford biosensing spin-out Nirmidas Biotech said this week that it has closed on a $2 million seed funding round.

According to the company, participants in the round include a leading venture capital fund, a life science angel investor, and the Stanford StartX Fund.

Nirmidas is developing a plasmonic gold chip platform for biomolecule detection and the detection of proteins in particular.

The technology comes out of the lab of Stanford researcher Hongjie Dai, who co-founded Nirmidas with CEO Meijie Tang, formerly a researcher at Lawrence Livermore National Laboratory. Currently operating with five employees, the company incorporated in September 2013 and began production of its initial research-focused chips in March this year.

The Scan

Steps for Quick Review

The US Food and Drug Administration is preparing for the quick review of drugs and vaccines for the Omicron variant, according to the Wall Street Journal.

Moving Away From Using Term 'Race'

A new analysis finds that geneticists are using the term "race" in their papers less than in years past, as Science reports.

Point of the Program

The Guardian writes that some scientists have called the design of a UK newborn sequencing program into question.

Science Papers Present Multi-Omic Analysis of Lung Cells, Regulation of Cardiomyocyte Proliferation

In Science this week: a multi-omic analysis of lung cells focuses on RIT1-regulated pathways, and more.